Search results
Results from the WOW.Com Content Network
Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. [3] This includes ovarian cancer , lung cancer , head and neck cancer , brain cancer , and neuroblastoma . [ 3 ]
A fundamental philosophy of medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens ...
The drug methotrexate (bottom) is an antimetabolite that interferes with the metabolism of folic acid (top). An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. [1]
This mechanism leads to specific patterns of damage in DNA, which can kill cancer cells but can also increase the risk of secondary tumors developing. [ 6 ] Platinum-based antineoplastic agents are sometimes described as "alkylating-like" due to similar effects as alkylating antineoplastic agents , although they do not have an alkyl group.
Pemetrexed is also recommended in combination with carboplatin and pembrolizumab for the first-line treatment of advanced non-small cell lung cancer. [12] [13] However, the relative efficacy or toxicity of pemetrexed-cisplatin versus pemetrexed-carboplatin has not been established beyond what is generally thought about cisplatin or carboplatin doublet drug therapy.
Download as PDF; Printable version ... Mechanism of action ... Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive ...
These plots were first introduced in a 1970 paper by R. A. More O’Ferrall to discuss mechanisms of β-eliminations [2] and later adopted by W. P. Jencks in an attempt to clarify the finer details involved in the general acid-base catalysis of reversible addition reactions to carbon electrophiles such as the hydration of carbonyls.
The mechanism of antineoplastic action for lobaplatin has not been studied in great detail. The results of current mechanistic studies suggest that lobaplatin is a DNA cross linking antineoplastic agent and has a similar platinum-induced cytotoxicity mechanism to other platin metallodrugs (i.e., cisplatin and oxaliplatin).